Thomas Knittel

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden.

InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden.

InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.